Wassim Kassouf

Jan 4, 2025 | cuaj.ca | Wassim Kassouf

License You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association.

Jan 5, 2024 | mdpi.com | Andres Llano |Amy Chan |Cynthia Kuk |Wassim Kassouf

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Dec 13, 2023 | bpspubs.onlinelibrary.wiley.com | Eva Michaud |Jose Joao Mansure |Wassim Kassouf

Bladder cancer is a prevalent malignancy with significant morbidity and mortality. Over the years, the landscape of bladder cancer treatment has witnessed notable advancements, particularly in the realm of immunotherapy. Immunotherapy has emerged as a promising adjunct to organ-preserving approaches, harnessing the immune system's potential to target and eliminate cancer cells.